DACIHEP contains daclatasvir, which works by inhibiting the hepatitis C virus, blocking its ability to replicate in liver cells. This drug is used in combination with other antiviral medications for the effective treatment of chronic hepatitis C. It helps reduce viral load and improve liver function.
The product is used for:
Chronic hepatitis C (in combination with other antiviral medications)
Viral load that is unresponsive to monotherapy
Pre-transplantation treatment for patients with chronic hepatitis C
DACIHEP is taken orally, typically 1 tablet (60 mg) once daily, with or without food, as prescribed by the doctor. Treatment duration may vary, depending on the treatment regimen established by the specialist.
Contraindications:
Hypersensitivity to daclatasvir or other components of the product
Severe liver diseases in decompensated stage
Pregnancy and breastfeeding (under medical supervision)
Co-administration with certain other antiviral drugs without medical control
Side Effects:
Headache
Fatigue
Nausea and dyspepsia
Loss of appetite
Allergic reactions (rash, itching)
